Subscribe
hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
20 March 2018Americas

Non-profit asks US government to take Gilead hepatitis C patent

A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Kite and Gadeta team up in cancer fight
23 July 2018   Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.
Asia
MSF challenges Gilead patent application in China
21 December 2017   Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Kite and Gadeta team up in cancer fight
23 July 2018   Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.
Asia
MSF challenges Gilead patent application in China
21 December 2017   Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More on this story

Americas
Kite and Gadeta team up in cancer fight
23 July 2018   Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.
Asia
MSF challenges Gilead patent application in China
21 December 2017   Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler